ISRCTN14340698CompletedPhase 1
Phase I trial: Labcorp Drug Development Study: 8479217 [The full scientific title will be published within 30 months after the end of the trial]
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Bergenbio ASA
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Exclusion Criteria
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A Phase I, open-label trial to investigate pharmacokinetics, safetyand tolerability of TMC125 at steady-state in treatment-experiencedHIV-1 infected children.HIV-1MedDRA version: 8.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2006-002183-26-DETibotec Pharmaceuticals Ltd40
Active, not recruiting
Phase 1
A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.EUCTR2006-002183-26-GBTibotec Pharmaceuticals Ltd42
Completed
Phase 1
Phase 1 trial: Labcorp code 8501022Healthy volunteersISRCTN13265717Albireo (Sweden)76
Active, not recruiting
Phase 1
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
Recruiting
Not Applicable
A Phase 1 trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies.relapsed or refractory lymphoid malignancy, relapsed/refractory multiple myeloma, relapsed/refractory Hodgkins lymphoma, relapsed/refractory peripheral T-cell lymphoma, relapsed/refractory cutaneous T-cell lymphoma, subtypes mycosis fungoides and Sézary syndrome, relapsed/refractory T-cell Prolymphocytic leukemia. Note: Recruitment to the CTCL and T-PLL cohorts was halted on 01 March 2021.Relapsed/ refractory Hematologic Malignancies10025319NL-OMON52700Mundipharma Research Limited10